Clinical trials
Polycythemia clinical trials
Below are recruiting polycythemia clinical trials, each written for real people, not researchers. We’re tracking 50 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06905106Recruiting
Polycythemia proteins and red blood cell study
This trial studies proteins and red blood cell production in people with polycythemia (high red blood cell count) to understand its causes. It may help improve care for patients with this condition.
DijonAges 18 years+ - NCT07357727RecruitingPhase 3
Study of Pelabresib and Ruxolitinib for Myelofibrosis
This trial tests a combination of two drugs (pelabresib and ruxolitinib) for people with myelofibrosis whose spleen is enlarged and who have bothersome symptoms. It aims to see if adding pelabresib to standard care helps control the disease better.
Berkeley Heights, New JerseyAges 18 years+ - NCT04282187RecruitingPhase 2
Decitabine plus targeted drugs for advanced blood cancer blast phase
This Phase 2 trial tests whether adding decitabine to one of three targeted medicines (ruxolitinib, fedratinib, or pacritinib) can improve outcomes in people with advanced myeloproliferative neoplasms that are progressing to a blast phase. It may help control the disease by combining blood-cancer chemotherapy with drugs that block disease-driving signaling.
Seattle, WashingtonAges 18 years+ - NCT04655092RecruitingPhase 3
Extension study for people finishing prior P1101 treatment
This is an “extension” trial for people who already completed a 52-week P1101 study and agreed to continue. It tests whether continuing P1101 after the original study is safe and beneficial for certain patients.
Toon-shi, EhimeAges 20 years+ - NCT05031897RecruitingPhase 2
Haplo transplant with reduced donor mismatch and radiation
This trial tests a special bone marrow/stem cell transplant approach using a partially matched family donor, along with conditioning treatment that involves radiation. It aims to help treat certain blood cancers by replacing damaged blood-forming cells with new ones from the donor.
Philadephia, PennsylvaniaAges 18 years+ - NCT05123365RecruitingPhase 1/Phase 2
Testing a dose of N-acetylcysteine for certain blood cancers
This Phase 1/2 study tests what dose of N-acetylcysteine (NAC) is safe and potentially helpful for people with essential thrombocythemia, polycythemia vera, or myelofibrosis. It focuses on people who still have symptoms and meet blood and health requirements so researchers can monitor side effects and symptom changes.
Irvine, CaliforniaAges 18 years+ - NCT05198960RecruitingPhase 3
Blood thinner drugs vs aspirin to prevent clot problems
This trial compares apixaban or rivaroxaban (blood thinners) against aspirin to prevent future clot-related complications in people with certain bone marrow diseases (PV, ET, or pre-PMF) that have a specific JAK2 mutation. It may help lower the risk of clots, but it also carefully considers bleeding risk.
AngersAges 18 years+ - NCT05440838Recruiting
Study factors that predict response to first-line blood cancer therapy
This study looks for factors that may predict how well people with polycythemia vera, essential thrombocythemia, or pre-myelofibrosis respond to first treatments such as hydroxyurea or pegylated interferon. It may help doctors choose better treatments by learning what differences affect outcomes.
AngersAges 18 years+ - NCT05835466RecruitingPhase 2
Reparixin for myelofibrosis patients who can’t use JAK inhibitors
This Phase 2 study tests reparixin, a drug aimed at reducing problems caused by myelofibrosis (bone marrow scarring). It focuses on people who have intermediate-2 or higher risk myelofibrosis and either didn’t respond to JAK inhibitor treatment or can’t tolerate it, to see if symptoms and disease markers improve.
Tampa, FloridaAges 18 years+ - NCT05870475RecruitingPhase 2
Interferon plus ruxolitinib for hydroxyurea-resistant polycythemia vera
This Phase 2 trial tests a combination of pegylated interferon and ruxolitinib in adults with polycythemia vera who can’t tolerate hydroxyurea or don’t respond well to it. If you qualify, it may help control blood counts and disease symptoms when standard treatment hasn’t worked.
TianjinAges 18 years+ - NCT06038630RecruitingPhase 2
Xenon gas MRI study for lung and heart health
This study uses a special MRI scan (Xenon gas imaging) to look at how well your lungs and heart are working. It is for people with certain lung conditions, those getting blood transfusions or phlebotomy, or healthy volunteers.
Durham, North CarolinaAges 18 years+ - NCT06063486RecruitingPhase 2
Curcumin for inflammation and symptoms in blood disorders
This trial tests whether curcumin, a natural compound found in turmeric, can reduce inflammation and improve symptoms like fatigue in people with certain blood disorders that cause low blood counts or overproduction of blood cells. It is for patients with clonal cytopenia of uncertain significance, low-risk myelodysplastic syndrome, or myeloproliferative neoplasms (polycythemia vera, essential thrombocytosis, or myelofibrosis) who have bothersome symptoms.
Los Angeles, CaliforniaAges 18 years+ - NCT06073847Recruiting
Safety study of fedratinib in Korean patients with myelofibrosis
This study looks at the safety of the drug fedratinib in Korean patients with myelofibrosis. It will help doctors better understand how well patients tolerate the drug when it's used as approved.
SeoulAges 19 years+ - NCT06378437RecruitingPhase 1
GLB-001 for blood cancers that have returned or not responded
This trial is testing a new drug called GLB-001 for people with certain blood cancers or bone marrow disorders that have not gotten better with standard treatments. The goal is to see if the drug is safe and how well it works.
Hefei, AnhuiAges 18 years+ - NCT07203768Recruiting
Study on how essential thrombocythemia evolves into polycythemia vera
This study watches how a blood condition called essential thrombocythemia (ET) changes into another condition called polycythemia vera (PV) in people with a specific JAK2 mutation. It aims to learn more about these changes and what happens to patients over time.
Rochester, MinnesotaAges 18–100 - NCT06516406Recruiting
Ruxolitinib study for primary and secondary myelofibrosis
This study follows patients with myelofibrosis (a type of bone marrow cancer) who are already taking or have taken ruxolitinib. Researchers will review medical records to understand how well the medicine works in everyday practice.
Cosenza, CalabriaAges 18 years+ - NCT06517875RecruitingPhase 2
Testing momelotinib plus luspatercept for transfusion-dependent myelofibrosis
This study tests a combination of two drugs, momelotinib and luspatercept, for people with myelofibrosis who need regular red blood cell transfusions. The goal is to see if the combination can reduce transfusion needs and improve symptoms.
Ann Arbor, MichiganAges 18 years+ - NCT06541249RecruitingPhase 2
Adding methotrexate for blood cancers not controlled by current therapy
This trial is testing whether adding a low dose of methotrexate (a medicine often used for arthritis) can help people with certain blood cancers (myelofibrosis, polycythemia vera, or essential thrombocythemia) whose current treatments are not controlling their symptoms or blood counts well enough.
New York, New YorkAges 18 years+ - NCT06734637Recruiting
Peginterferon for essential thrombocythemia and polycythemia vera
This trial tests a medicine called peginterferon for people with two blood disorders: essential thrombocythemia (too many platelets) and polycythemia vera (too many red blood cells). The goal is to see if peginterferon can help control these conditions and is safe.
Wuhan, HubeiAges 18 years+ - NCT06770842RecruitingPhase 2
Study of two drugs for myelofibrosis with prior treatment
This trial tests a combination of two medications, ropeginterferon alfa-2b and ruxolitinib, for people with myelofibrosis whose spleen has not shrunk enough or has grown back while on ruxolitinib. The goal is to see if adding the newer drug can improve outcomes.
Hong KongAges 18 years+ - NCT06976918Recruiting
Myelofibrosis and Anemia Research Study
This study follows people with myelofibrosis and anemia who are starting a new treatment. It aims to learn more about the disease and how treatments work in real life.
Multiple LocationsAges 18 years+ - NCT06991400Recruiting
A study of a new surgical approach for TTTS and TAPS
This trial tests a new surgical technique for twin-to-twin transfusion syndrome (TTTS) or twin anemia-polycythemia sequence (TAPS). It places a stitch through the amniotic sac during surgery to see if it helps. The study is for pregnant people between 18 and 23 weeks with healthy cervical length and a safe access point for surgery.
Cincinnati, OhioAges 18 years+ - NCT07340138RecruitingPhase 1
Pelabresib and Ruxolitinib combo for myelofibrosis in Japan
This study tests adding a new drug (pelabresib) to the standard treatment (ruxolitinib) for Japanese people with myelofibrosis. The goal is to see if the combination helps control symptoms like an enlarged spleen.
Kamogawa, ChibaAges 18 years+ - NCT02897297Recruiting
Brest study for blood disorders tracking
This is an observational study that follows people with certain blood disorders. It aims to learn more about how these conditions behave in real life, which can help improve future care.
BrestAges Any age
Hear when a new Polycythemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for polycythemia?
- Yes. Clin2 currently lists 50 recruiting polycythemia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a polycythemia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a polycythemia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.